B
Beatrice Waser
Researcher at University of Bern
Publications - 125
Citations - 10597
Beatrice Waser is an academic researcher from University of Bern. The author has contributed to research in topics: Receptor & Somatostatin receptor. The author has an hindex of 52, co-authored 125 publications receiving 9784 citations. Previous affiliations of Beatrice Waser include University of Texas MD Anderson Cancer Center & Salk Institute for Biological Studies.
Papers
More filters
Journal ArticleDOI
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Jean Claude Reubi,Jean-Claude Schär,Beatrice Waser,Sandra Wenger,A. Heppeler,Jörg S. Schmitt,Helmut R. Mäcke +6 more
TL;DR: In vivo somatostatin receptor scintigraphy using Octreoscan is a valuable method for the visualisation of human endocrine tumours and their metastases and small structural modifications, chelator substitution or metal replacement were shown to considerably affect the binding affinity.
Journal ArticleDOI
Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
TL;DR: It is concluded that sst2, with high affinity for current radiopharmaceuticals such as Octreoscan, is predominantly expressed in a majority of tumours and suggests the existence of an as yet unknown subtype in selected tumours.
Journal ArticleDOI
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
Jean Claude Reubi,Beatrice Waser +1 more
TL;DR: This review summarises the investigations of the concomitant expression of 13 different peptide receptors, in more than 100 neuroendocrine tumours of the human intestine, pancreas and lung, using in vitro receptor autoradiography with subtype-selective ligands and reveals a characteristic receptor pattern in several tumour types.
Journal ArticleDOI
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Mihaela Ginj,Hanwen Zhang,Beatrice Waser,Renzo Cescato,Damian Wild,Xuejuan Wang,Judit Erchegyi,Jean Rivier,Helmut R. Mäcke,Jean Claude Reubi +9 more
TL;DR: Somatostatin antagonist radiotracers are preferable over agonists for the in vivo targeting of sst3- or sst2-expressing tumors, and antagonists for other peptide receptors need to be evaluated in nuclear oncology as a result of this paradigm shift.
Journal ArticleDOI
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
TL;DR: The GLp-1 receptors may represent a novel molecular target for in vivo scintigraphy and targeted radiotherapy for a variety of GLP-1 receptor-expressing tumors.